title: Recent advances and new opportunities for targeting human dendritic cells in situ.
abstract: Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-targeting via nanoparticles suggest that combinatorial targeting of multiple human DC subsets may further improve the efficacy of DC targeting.
authors.affiliation: Yale University ; New Haven, CT USA.
authors.forename: Madhav V
authors.initials: MV
authors.lastname: Dhodapkar
authors.affiliation: Yale University ; New Haven, CT USA.
authors.forename: Kavita M
authors.initials: KM
authors.lastname: Dhodapkar
keywords: DC, dendritic cells; NP, nanoparticles; TLR, toll-like receptors; dendritic cells; immunotherapy; vaccine